SG11201901999XA - Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making - Google Patents
Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of makingInfo
- Publication number
- SG11201901999XA SG11201901999XA SG11201901999XA SG11201901999XA SG11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- loxl2
- methods
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 | |
| PCT/US2017/050332 WO2018048943A1 (fr) | 2016-09-07 | 2017-09-06 | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901999XA true SG11201901999XA (en) | 2019-04-29 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901999XA SG11201901999XA (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (fr) |
| EP (1) | EP3510023A4 (fr) |
| JP (1) | JP7079772B2 (fr) |
| KR (1) | KR102587178B1 (fr) |
| CN (1) | CN109983006B (fr) |
| AU (1) | AU2017324445A1 (fr) |
| BR (1) | BR112019004517A2 (fr) |
| CA (1) | CA3036064A1 (fr) |
| EA (1) | EA201990621A1 (fr) |
| IL (1) | IL265192A (fr) |
| MA (1) | MA46204A (fr) |
| MX (1) | MX2019002615A (fr) |
| SG (1) | SG11201901999XA (fr) |
| WO (1) | WO2018048943A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144702A1 (fr) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| SG11201707246YA (en) | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| EP3414229B1 (fr) * | 2016-02-09 | 2021-06-16 | Pharmakea, Inc. | Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
| EP3509594A4 (fr) | 2016-09-07 | 2020-05-06 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| HUP0204272A3 (en) | 2000-01-18 | 2005-03-29 | Pfizer Prod Inc | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| EP1638551B1 (fr) | 2003-05-19 | 2011-12-21 | Irm Llc | Composes immunosuppresseurs et compositions |
| BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| EP1735268B1 (fr) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Antagonistes des recepteurs opioides |
| MXPA06012333A (es) | 2004-04-30 | 2007-01-17 | Takeda Pharmaceutical | Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13. |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| MX2007002842A (es) | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
| JP2008512440A (ja) | 2004-09-10 | 2008-04-24 | ファイザー・プロダクツ・インク | ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法 |
| WO2006052546A2 (fr) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Dérivés hétéroaryles de pyrazolylméthyle |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| CA2593858A1 (fr) | 2005-01-31 | 2006-08-10 | Min Ge | Composes bicycliques antidiabetiques |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| EP1915369A4 (fr) | 2005-08-11 | 2010-09-08 | Merck Frosst Canada Ltd | Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) * | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| JP2009523820A (ja) | 2006-01-23 | 2009-06-25 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼの三環系抑制剤 |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| EP2121703A4 (fr) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | Dérivés de thiénopyrimidin-4-one et de thiénopyridazin-7-one en tant qu'antagonistes du mch rl |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| EP2537529B1 (fr) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Anticorps inhibiteurs dirigés contre loxl2, et procédés d'utilisation associés |
| MX2012001156A (es) | 2009-07-28 | 2012-05-08 | Anacor Pharmaceuticals Inc | Moleculas que contienen boro trisustituidas. |
| JP2013502437A (ja) | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス，インク． | 治療方法及び組成物 |
| CN103370080A (zh) | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法 |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| WO2012068450A1 (fr) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Dérivés pyrrolopyridine et pyrrolopyrimidine à substitution cyclobutyle utilisés comme inhibiteurs des jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| AU2012325909B2 (en) | 2011-10-20 | 2016-06-09 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| RU2632899C2 (ru) | 2012-04-25 | 2017-10-11 | Раквалиа Фарма Инк. | Амидопроизводные как блокаторы ttx-s |
| US20140120102A1 (en) * | 2012-10-30 | 2014-05-01 | Gilead Sciences, Inc. | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| CN104854086B (zh) | 2012-12-18 | 2017-06-27 | Ea制药株式会社 | 杂环酰胺衍生物和含有其的药物 |
| WO2016020732A1 (fr) | 2014-08-05 | 2016-02-11 | The University Of British Columbia | Modulateurs de caspase 6 |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| SG11201706451TA (en) | 2015-02-15 | 2017-09-28 | Hoffmann La Roche | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
| WO2016144702A1 (fr) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| SG11201707246YA (en) * | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| EP3509594A4 (fr) | 2016-09-07 | 2020-05-06 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
-
2017
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active IP Right Grant
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 BR BR112019004517A patent/BR112019004517A2/pt unknown
- 2017-09-06 MX MX2019002615A patent/MX2019002615A/es unknown
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 CA CA3036064A patent/CA3036064A1/fr active Pending
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/fr unknown
- 2017-09-06 EP EP17849479.5A patent/EP3510023A4/fr active Pending
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004517A2 (pt) | 2019-08-13 |
| EP3510023A1 (fr) | 2019-07-17 |
| AU2017324445A1 (en) | 2019-04-11 |
| KR102587178B1 (ko) | 2023-10-06 |
| US20190202805A1 (en) | 2019-07-04 |
| CA3036064A1 (fr) | 2018-03-15 |
| MA46204A (fr) | 2021-03-17 |
| EP3510023A4 (fr) | 2020-03-18 |
| IL265192A (en) | 2019-05-30 |
| CN109983006B (zh) | 2022-02-25 |
| US10774069B2 (en) | 2020-09-15 |
| JP2019532919A (ja) | 2019-11-14 |
| WO2018048943A1 (fr) | 2018-03-15 |
| CN109983006A (zh) | 2019-07-05 |
| JP7079772B2 (ja) | 2022-06-02 |
| KR20190052040A (ko) | 2019-05-15 |
| US20200361901A1 (en) | 2020-11-19 |
| MX2019002615A (es) | 2019-10-15 |
| US11459309B2 (en) | 2022-10-04 |
| EA201990621A1 (ru) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901999XA (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201408140QA (en) | Crystalline forms of an androgen receptor modulator | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201906222WA (en) | Jak1 selective inhibitors |